Everolimus is an active agent in medullary thyroid cancer: A clinical and in vitro study

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 7, 2012, Pages 1563-1572

  Faggiano, A ^a   Ramundo, V ^b   Dicitore, A ^c   Castiglioni, S ^c   Borghi, M O ^c,d   Severino, R ^b   Ferolla, P ^e   Crino L ^e   Abbruzzese, A ^f   Sperlongano, P ^f   Caraglia, M ^f   Ferone, D ^g   Hofland, L ^h   Colao, A ^b   Vitale, G ^c,d  

^a IRCCS SDN   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Multidisciplinary Group for Diagnosis and Therapy of Neuroendocrine Tumours   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Calcitonin; Everolimus; Medullary thyroid cancer; Neuroendocrine tumour; Somatostatin analogues

Indexed keywords

BETA GALACTOSIDASE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DRUG DERIVATIVE; EVEROLIMUS; IMIDAZOLE DERIVATIVE; RAPAMYCIN; ZOLEDRONIC ACID;

AGED; APOPTOSIS; ARTICLE; BLOOD; CASE REPORT; CELL AGING; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; THYROID TUMOR; THYROIDECTOMY; TREATMENT OUTCOME; WESTERN BLOTTING;

AGED; APOPTOSIS; BETA-GALACTOSIDASE; BLOTTING, WESTERN; CALCITONIN; CELL AGING; CELL CYCLE; CELL PROLIFERATION; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; SIROLIMUS; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 84863095977     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01438.x     Document Type: Article

References (27)

1. Leboulleux S, Baudin E, Travagli JP, et al. Medullary thyroid carcinoma. Clin Endocrinol. 2004; 61: 299-310.
2. Sippel RS, Kunnimalaiyaan M, Chen H. Current management of medullary thyroid cancer. Oncologist. 2008; 13: 539-47.
3. Papotti M, Kumar U, Volante M, et al. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol. 2001; 54: 641-9.
4. Zatelli MC, Piccin D, Tagliati F, et al. Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. J Clin Endocrinol Metab. 2006; 91: 2218-24.
5. Lupoli G, Cascone E, Arlotta F, et al. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide. Cancer 1996; 78: 1114-8.
6. Vainas I, Koussis Ch, Pazaitou-Panayiotou K, et al. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma. J Exp Clin Cancer Res. 2004; 23: 549-59.
7. Vitale G, Tagliaferri P, Caraglia M, et al. Slow release lanreotide in combination with interferon-α2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab. 2000; 85: 983-8.
8. Vitale G, Caraglia M, Ciccarelli A, et al. Current approaches in the therapy of medullary thyroid carcinoma. Cancer. 2001; 91: 1797-808.
9. Zatelli MC, Tagliati F, Taylor JE, et al. Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. Horm Metab Res. 2002; 34: 229-33.
10. Shida T, Kishimoto T, Furuya M, et al. Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumours. Cancer Chemother Pharmacol. 2010; 65: 889-93.
11. Righi L, Volante M, Rapa I, et al. Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumours of the lung. Endocr Relat Cancer. 2010; 17: 977-87.
12. Zitzmann K, De Toni EN, Brand S, et al. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumour cells. Neuroendocrinology. 2007; 85: 54-60.
13. Grozinsky-Glasberg S, Franchi G, Teng M, et al. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology. 2008; 87: 168-81.
14. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumours: results of a phase II study. J Clin Oncol. 2008; 26: 4311-8.
15. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumours after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010; 28: 69-76.
16. Seeliger H, Guba M, Kleespies A, et al. Role of mTOR in solid tumour systems: a therapeutical target against primary tumour growth, metastases, and angiogenesis. Cancer Metastasis Rev. 2007; 26: 611-21.
17. Lin CI, Whang EE, Donner DB, et al. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res. 2010; 8: 1217-26.
18. Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, et al. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. Mol Cell Endocrinol. 2010; 315: 87-94.
19. Vitale G, van Eijck CH, van Koetsveld PM, et al. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg. 2007; 246: 259-68.
20. Vitale G, de Herder WW, van Koetsveld PM, et al. IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumour cell growth in vitro. Cancer Res. 2006; 66: 554-62.
21. Wells SAJr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010; 28: 767-72.
22. Saretzki G. Cellular senescence in the development and treatment of cancer. Curr Pharm Des. 2010; 16: 79-100.
23. Lleonart ME, Artero-Castro A, Kondoh H. Senescence induction; a possible cancer therapy. Mol Cancer. 2009; 8: 3-14.
24. Korotchkina LG, Leontieva OV, Bukreeva EI, et al. The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. Aging. 2010; 2: 344-52.
25. Demidenko ZN, Blagosklonny MV. Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle. 2008; 7: 3355-61.
26. Schug TT. mTOR favors senescence over quiescence in p53-arrested cells. Aging. 2010; 2: 327-8.
27. Ota H, Eto M, Ako J, et al. Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. J Am Coll Cardiol. 2009; 53: 2298-305.